Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sorafenib

DRUG

Doxorubicin

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow

10604

Memorial Sloan Kettering West Harrison, Harrison

11570

Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

National Comprehensive Cancer Network

NETWORK

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01840592 - Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | Biotech Hunter | Biotech Hunter